At the time of writing, five anti-CD19 CAR T-cell products are approved by U.S. Food and Drug Administration for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin lymphoma, pediatric acute lymphoblastic leukemia, multiple myeloma. T cells chronic lymphocytic myeloid less common malignancies such as lymphomas Hodgkin lymphoma being tested early-phase clinical tri...

The association between non-Hodgkin lymphoma, including chronic lymphocytic leukemia, and aggressive skin cancers is well established. This review highlights existing data that address increased incidence and clinical characteristics of skin cancers in patients with non-Hodgkin lymphoma-specifically, chronic lymphocytic leukemia. Patients with non-Hodgkin lymphoma have worse outcomes when melan...

Type 2 diabetes mellitus is associated with altered immune function and chronic inflammation. Both of these immune conditions are implicated in the pathogenesis of non-Hodgkin lymphoma. The authors performed a systematic review to summarize findings from the current literature on the association between history of type 2 diabetes mellitus and risk of non-Hodgkin lymphoma. Ten case-control studi...

Localized Nodular Lymphocyte Predominant Hodgkin Lymphoma is a rare disease with an overall good prognosis but frequent late relapses. Due to it's rarity there is no standard therapeutic approach and pathological diagnosis may be hard. In this paper we discuss the technical aspects of the radiation therapy and histological issues. The new fields reductions proposed for classical Hodgkin lymphom...

BACKGROUND Common genetic variants in immune and inflammatory response genes can affect the risk of developing non-Hodgkin lymphoma. We aimed to test this hypothesis using previously unpublished data from eight European, Canadian, and US case-control studies of the International Lymphoma Epidemiology Consortium (InterLymph). METHODS We selected 12 single-nucleotide polymorphisms for analysis,...

We describe a rare case of Castleman disease associated de novo with Hodgkin lymphoma. The incidence of Castleman disease is rare; only a few studies have described it in de novo association with Hodgkin lymphoma. The patient described here complained of unique evolutionary axillary adenopathy. A positron-emission tomography/computed tomography scan revealed hypermetabolic activity in this area...

modern leukemia and lymphoma sequencing standards, is an improvement in signal-to-noise ratio for Hodgkin lymphoma given the incredible rarity of the Reed-Sternberg cell in its background nest of inflammatory infiltrate. Previous studies relying on laser capture microdissection could also increase the signal-to-noise ratio, but at the cost of time, effort, and still-low cell numbers. This work ...

Two hundred and ninety cases of non-Hodgkin's lymphoma from the Fars Province Cancer Registry and Mashad University Hospital were reviewed and classified according to the new International Working Formulation for clinical use. The cases fall into low-grade (35 male, 26 female), intermediate-grade (61 male, 26 female), and high-grade (84 male, 26 female) groups. Each group includes several ...

Lymphomas are classified as Hodgkin’s and Non-Hodgkin’s lymphomas (HL NHL) NHL being further sub-divided into B, T and Null cell categories on the basis of WHO classification. With a few exceptions worldwide, B-NHL are more common, accounting approximately 80-85% of all cases of NHL compared to T-NHL, which accounts for about 10-15% of all NHL cases. The incidence of NHL has shown a steady incr...

Abstract Background Malignant lymphoma accounts for nearly 20% of all mediastinal neoplasms in adults and 50% children. Hodgkin’s disease is the most common primary lymphoma. In non-Hodgkin’s lymphoma, two forms are lymphoblastic diffuse large B-cell The aim this study to implement diffusion MRI algorithm diagnosis differentiating Hodgkin's from non-Hodgkin's assessment post therapeutic respons...